Spotlight On Israel: Blossoming Targeted Cancer Therapy Startups
Executive Summary
Scrip sat down with the CEOs of three emerging oncology companies in Israel that are all focused on targeted cancer treatments, to find out about upcoming milestones and novel technologies that are budding in the country.
You may also be interested in...
Alnylam Set For Transformation As Patisiran Nears Market With Data Upgrade
Alnylam has outlined further data and analyses from the Phase III APOLLO study supporting the use of its selective interfering RNA agent, patisiran, as it nears the market for the treatment of hATTR amyloidosis.
Interview: Alnylam President On Patisiran Lift-Off Plans
Barry Greene, president of Alnylam, tells Scrip that the company is happy to consider risk-sharing with payers, as the firm is confident about the 'extreme value' that its RNAi therapeutic for hATTR amyloidosis will offer, if approved.
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.